Status:
COMPLETED
Assessment of the Impact of Gadolinium Injection on the Measurement of the QSM Signal
Lead Sponsor:
Fondation Ophtalmologique Adolphe de Rothschild
Conditions:
White Matter Disease
Eligibility:
All Genders
18+ years
Brief Summary
Patients meeting the inclusion and non-inclusion criteria will be offered to participate in the study. If they agree, they will perform an MRI without injection to obtain the QSM then perform the MRI ...
Detailed Description
Patients meeting the inclusion and non-inclusion criteria will be offered to participate in the study. If they agree, they will perform an MRI without injection to obtain the QSM then perform the MRI ...
Eligibility Criteria
Inclusion
- patients over 18 years old
- with an inflammatory CNS pathology
- to benefit as part of care from an MRI with injection of gadolinium
- consent to participate in the study
- beneficiary of a social protection scheme
Exclusion
- pregnant or breastfeeding woman
- patient benefiting from a legal protection measure
- Patient having performed more than 3 MRI exams with gadolinium injection during his life
- Secondary exclusion criteria :
- motion artifact not allowing image interpretation
- patient who has not completed one of the following sequences: T1 anatomical, FLAIR, or QSM pre-gadolinium injection.
- Secondarily excluded patients will be replaced up to a maximum of 25 patients.
Key Trial Info
Start Date :
January 21 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 19 2023
Estimated Enrollment :
73 Patients enrolled
Trial Details
Trial ID
NCT04906941
Start Date
January 21 2022
End Date
July 19 2023
Last Update
January 5 2026
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hhopital fondation adolphe de rothschild
Paris, Paris, France, 75019